Navigation Links
Forest and Cypress Announce FDA Approval of Savella(TM) for the Management of Fibromyalgia
Date:1/14/2009

er potency than serotonin (in-vitro), two neurotransmitters thought to a play a central role in the symptoms of fibromyalgia. Savella will be marketed by Forest and its licensor, Cypress Bioscience. Pierre Fabre, who originally developed and sells milnacipran outside the U.S., licensed the rights for North America to Cypress Bioscience.

About Fibromyalgia

Fibromyalgia is a chronic and debilitating condition characterized by widespread pain and decreased physical functioning. According to the American College of Rheumatology fibromyalgia is estimated to affect over 6 million Americans. It is most often diagnosed in the primary care setting and is the second most commonly diagnosed condition in rheumatology clinics in the United States after osteoarthritis. Despite the high prevalence and severity of this condition, there are limited treatment options specifically approved for fibromyalgia in the United States.

Important Safety Information

Savella is a selective serotonin and norepinephrine inhibitor (SNRI), similar to some drugs used for the treatment of depression and other psychiatric disorders. Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of such drugs in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on Savella should be monitored appropriate
'/>"/>

SOURCE Forest Laboratories, Inc.; Cypress Bioscience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Third Quarter Earnings
2. Forest Laboratories Announces Executive Exercised Stock Options With Intent to Hold Shares
3. Forest Laboratories Responds To Unsolicited Mini-Tender Offer
4. Forest Laboratories, Inc. Reports Fiscal Second Quarter 2009 Earnings per Share of $0.80
5. Lupin Enters into a Marketing Alliance with Forest Laboratories, Inc. for AeroChamber Plus(R) Brand in the US - Extends its Franchise with Pediatricians
6. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
7. Lake Forest, CA: SpeechPhone Launches Handsfree Driving Solution Just in Time to Comply with New Handsfree Driving Laws
8. Wake Forest Class Taps Recordant for Web-Based Search and Playback of Course Materials
9. Cleaner Air May Threaten Amazon Rainforest
10. Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Licensing Payment
11. Metrologic and Wake Forest University Baptist Medical Center Sponsored Healthcare Educational Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. 30, 2014 ... transplantation is nothing new. The first kidney transplant took ... 1963 and the first human heart transplant in 1967. By ... entire face. One major organ still eludes the transplant ... of U.S. scientists has its way, that dream may become ...
(Date:10/31/2014)... News) -- The number of medical malpractice payments in ... to a new study. And compensation payment amounts ... or declined in recent years, researchers report online Oct. ... Association . "For many physicians, the prospect of ... of modern clinical practice," researchers, led by Michelle Mello, ...
(Date:10/31/2014)... WASHINGTON, DC (October 31, 2014) — A new ... (Milken Institute SPH) at the George Washington University ... for pregnant women who are enrolled in Covered ... which includes the Comprehensive Perinatal Services Program (CPSP). ... the nation,s most successful programs ever developed for ...
(Date:10/30/2014)... day provide new treatments for injuries and damage to ... Cartilage, for example, is a hard material that caps ... smoothly. UC Davis biomedical engineers, exploring ways to toughen ... the body, report new developments this week in the ... . , "The problem with engineered tissue is that ...
(Date:10/30/2014)... group at the DFG Research Center for Regenerative Therapies ... (CRTD) demonstrated for the first time the in vitro ... dimensions from mouse embryonic stem cells. Correct spatial organization ... dorsal/ventral axis was observed., This study has been published ... Reports " on 30.10.2014 ., For many years Elly ...
Breaking Medicine News(10 mins):Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:Fewer Malpractice Claims Paid in U.S. 2Health News:Report examines health care challenges for pregnant women enrolled in covered California 2Health News:Making lab-grown tissues stronger 2Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2
... that combines 2 medications , , SUNDAY, March 30 (HealthDay News) ... make sense of a trial showing that a drug can ... apparent benefit to people at high risk of heart attack ... well-known statin -- simvastatin -- with ezetimibe, which also lowers ...
... use with angioplasty following a heart attack, the anticoagulants ... measures within 90 minutes after the procedure, while patients ... a lower risk of major adverse cardiac events within ... to a JAMA study being released early online March ...
... risk and don,t increase mortality probability , , SUNDAY, March ... placed in diseased coronary arteries to keep them open, ... patients, new research shows. , In the largest study ... the drug in question retards the growth of arterial ...
... to Join Nation,s Largest RN ... Organization, ... registered nurses to have a stronger voice to speak,out for patients and ... to win union collective bargaining,rights., RNs at Cypress Fairbanks Medical Center ...
... deaths could be avoided with lifestyle changes, experts say, ... that could cut cancer deaths in half. , Well, ... American Cancer Society report that said as many as ... lifestyle changes, such as quitting smoking, maintaining a healthy ...
... mice was important protective mechanism, researchers say , , FRIDAY, March ... a critical role in protecting the heart during a heart ... It was already known that Gi increased activity in a ... helping the heart adapt to damage or if it actually ...
Cached Medicine News:Health News:Cholesterol Drug Controversy Continues 2Health News:Cholesterol Drug Controversy Continues 3Health News:Comparison of anticoagulants for angioplasty show similar outcomes 2Health News:Drug-Eluting Stents Safe After Heart Attack 2Health News:First Unionized Hospital in Texas 2Health News:First Unionized Hospital in Texas 3Health News:You May Be the Key to Cancer Prevention 2Health News:You May Be the Key to Cancer Prevention 3Health News:Key Protein Limits Damage of Heart Attack 2
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... , Oct. 30, 2014 China Biologic Products, ... leading fully integrated plasma-based biopharmaceutical company in ... to release third quarter 2014 financial results on Wednesday, ... The Company,s management will hold a conference call ... 2014, which is 8:30 p.m., Beijing Time on November ...
(Date:10/30/2014)... October 30, 2014 , ... LGG contribuye a adquirir tolerancia a la proteína ... la proteína de la leche de la vaca (APLV) ... infancia. Hasta ahora, la APLV se trataba eliminando ... ha demostrado que es posible adquirir tolerancia oral ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3China Biologic to Report Third Quarter 2014 Financial Results 2Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3
... 2010 Reportlinker.com announces that a new market research ... Toxicology and Pharmacology http://www.reportlinker.com/p0324751/Toxicology-and-Pharmacology.html ... Regulation; Technical, Political and Economic Challenges – key report ... are almost exclusively outsourced and the market is worth ...
... Nov. 3, 2010 Breast Cancer Action (BCA) learned today ... Lilly & Company via a billboard in Indianapolis have ... sick.  Tell them to stop" was rejected by every ... working within the guidelines of each billboard company contacted, ...
Cached Medicine Technology:Reportlinker Adds Toxicology and Pharmacology 2Reportlinker Adds Toxicology and Pharmacology 3Breast Cancer Message Barred in Eli Lilly's Hometown 2
World's first commercially available vacuum assisted biopsy device for MRI....
... you can perform stereotactic, ultrasound and MRI-guided ... of your office. Use the patented, FDA-cleared ... and more clinically advanced method of breast ... for the women who trust YOU.,9 Gauge ...
18" Penrose drains...
Offers a more constant suction profile than three-spring evacuators, resulting in the potential for improved tissue approximation and reduced risk of hematoma....
Medicine Products: